FDA Approves Gwyn Lo: New Once-Weekly Low-Dose Estrogen Contraceptive Patch Option
The U.S. Food and Drug Administration (FDA) has approved a new contraceptive option designed to give women more flexibility and choice in pregnancy prevention. Viatris Inc. announced that the FDA approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system), a once-weekly combined hormonal contraceptive patch intended for women who are appropriate candidates for combined hormonal contraception.
The approval introduces another non-invasive and reversible birth control option that delivers a low dose of estrogen through a weekly patch system. The new contraceptive patch is designed for women who prefer an alternative to daily oral contraceptive pills or other methods requiring more frequent attention.
While contraceptive choices are highly personal and depend on individual health factors, the availability of additional options may help women and healthcare providers select methods that better match personal preferences, lifestyles, and medical needs.
FDA Approval of Gwyn Lo Contraceptive Patch
The FDA approval of Gwyn Lo represents a significant development in women’s health and contraceptive care. The patch combines two hormones, norelgestromin and ethinyl estradiol, which work together as a combined hormonal contraceptive (CHC) to help prevent pregnancy.
Gwyn Lo delivers:
- Norelgestromin at 220 micrograms per day
- Ethinyl estradiol at 20 micrograms per day
The patch is designed to be applied once weekly for three consecutive weeks, followed by one patch-free week. This schedule provides a convenient alternative for women who may prefer weekly administration instead of remembering a daily contraceptive pill.
According to the company, Gwyn Lo is approved for women with a body mass index (BMI) below 30 kg/m² who are appropriate candidates for combined hormonal contraception.
How the Once-Weekly Patch Works
Gwyn Lo uses a transdermal delivery system, meaning the medication is absorbed through the skin rather than taken orally. The patch contains the active ingredients within a layered adhesive system that allows controlled hormone delivery throughout the seven-day wearing period.
The patch structure includes:
- A protective backing layer that provides support
- A medication-containing adhesive matrix
- A removable liner that protects the patch before use
After application, the system continuously releases hormones over the treatment period. This approach may provide convenience for individuals who prefer not to take medication every day.
Clinical Study Results Supporting Approval
The FDA approval was supported by data from the Phase 3 Luminous Study, which evaluated the effectiveness, safety, and performance of Gwyn Lo.
The study assessed contraceptive effectiveness using the Pearl Index, a measurement commonly used in contraceptive research to estimate pregnancy rates among users. In the efficacy evaluable group of women aged 18 to 35 years, the reported Pearl Index was 4.14.
Researchers also evaluated how well the patch stayed attached during daily activities. During the year-long clinical trial, only 1.3% of the nearly 39,790 patches applied completely detached, suggesting strong adhesion performance under typical use conditions.
The study also examined how bleeding patterns changed over time. Researchers reported that unscheduled bleeding and spotting decreased as participants continued using the patch, with improvements observed between the first and thirteenth cycles.
Reported Side Effects and Safety Information
Like other hormonal contraceptives, Gwyn Lo may cause side effects, and users should discuss their medical history with a healthcare professional before starting treatment.
In clinical studies, commonly reported side effects included:
- Application site irritation
- Redness at the application area
- Itching at the application site
- Bleeding between menstrual cycles
- Heavy withdrawal bleeding
- Nausea
The FDA-approved prescribing information includes important safety considerations. Gwyn Lo is not recommended for certain groups, including women who smoke and are over 35 years old because of an increased risk of serious cardiovascular events.
The product is also contraindicated for women with a BMI of 30 kg/m² or higher. Healthcare providers can help determine whether a combined hormonal contraceptive patch is an appropriate option based on medical history and individual risk factors.
Why More Contraceptive Options Matter
Unintended pregnancy continues to be an important public health concern in the United States. Research has shown that many women change or discontinue contraceptive methods because their current option does not meet their preferences, lifestyle needs, or expectations.
Factors influencing contraceptive choices can include:
- Convenience and ease of use
- Hormone preferences
- Side effects
- Personal health considerations
- Comfort with the method
- Ability to maintain a regular schedule
The introduction of weekly contraceptive options provides another choice for women who want a reversible method without daily medication requirements.
Healthcare professionals often emphasize that there is no single contraceptive method that works best for everyone. The right option depends on individual circumstances, health history, and personal priorities.
Availability of Gwyn Lo
Viatris has stated that Gwyn Lo is expected to become commercially available later in 2026. The company develops and supplies healthcare products globally, with a focus on expanding access to medicines and healthcare solutions.
The approval of Gwyn Lo adds to the range of contraceptive methods available in the United States and reflects ongoing innovation in women’s healthcare.
Conclusion
The FDA approval of Gwyn Lo marks a new development in contraceptive options by introducing a once-weekly, low-dose estrogen patch for eligible women. The transdermal system offers a reversible and non-invasive approach that may appeal to individuals seeking an alternative to daily birth control methods.
As with any medication, women should consult qualified healthcare providers to understand the benefits, risks, and whether Gwyn Lo is suitable for their specific health needs.
Greater availability of contraceptive choices allows individuals to make more informed decisions about reproductive health based on their personal preferences and medical circumstances.
Sources
- Viatris Inc. Press Release: FDA Approves Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system), July 29, 2026.
- Rossen LM, Hamilton BE, Abma JC, et al. Updated methodology to estimate overall and unintended pregnancy rates in the United States. National Center for Health Statistics. Vital and Health Statistics, Series 2, Number 201, 2023.
- National Center for Health Statistics. NCHS Rapid Surveys System: Contraception Use.
Disclaimer
This article is for informational and educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Contraceptive choices should be discussed with a qualified healthcare provider who can evaluate individual health conditions, risks, and personal needs. Always review the official prescribing information and safety warnings before starting any medication.